Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
Mithracin (plicamycin) is a small-molecule antibiotic derived from Streptomyces species, approved in 1970 primarily for treating testicular cancer and hypercalcemia associated with malignancy. It functions as a DNA-binding agent that intercalates into the double helix, disrupting transcription and inhibiting tumor cell growth. The drug has remained in limited clinical use for over 50 years due to its toxicity profile and the emergence of safer alternatives.
This legacy oncology asset faces declining demand as newer, better-tolerated agents dominate the market; commercial teams are likely small and focused on niche patient populations.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Mithracin offers limited career growth opportunity; the product is in late decline with minimal commercial infrastructure and no linked job openings. Career value lies primarily in regulatory expertise, supply chain management, or medical affairs roles focused on maintaining compliance and patient access for a legacy oncology asset.
Worked on MITHRACIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.